$MBIO
MUSTANG BIO, INC. Stock $mbio

$mbio Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000114420417058634 Filed on November 14, 2017

Income Statement

Concept	2017 Q3	2016 Q4	2016 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.600M	$1.000M	$1.100M
YoY Change	318.18%	1150.0%	1122.22%
% of Gross Profit
Research & Development	$500.0K	$6.830M	$500.0K
YoY Change	0.0%	798.68%	0.0%
% of Gross Profit
Depreciation & Amortization	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$7.084M	$7.830M	$1.670M
YoY Change	324.19%	832.14%	153.8%
Operating Profit	-$7.084M	-$7.831M	-$1.670M
YoY Change	324.19%	828.94%	153.8%
Interest Expense	$140.0K	-$920.0K	-$200.0K
YoY Change	-170.0%	1214.29%	233.33%
% of Operating Profit
Other Income/Expense, Net	$144.0K	-$917.0K	-$200.0K
YoY Change	-172.0%	1248.53%	244.83%
Pretax Income	-$6.940M	-$8.750M	-$1.870M
YoY Change	271.12%	861.54%	159.72%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.940M	-$8.748M	-$1.870M
YoY Change	271.12%	860.26%	161.17%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$265.0K	-$346.9K	-$74.15K
COMMON SHARES
Basic Shares Outstanding		13.08M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2016 Q4	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$67.30M	$27.50M	$11.10M
YoY Change	506.31%
Cash & Equivalents	$33.21M	$27.50M	$11.12M
Short-Term Investments	$34.10M
Other Short-Term Assets	$400.0K
YoY Change
Inventory
Prepaid Expenses	$414.0K	$0.00
Receivables
Other Receivables
Total Short-Term Assets	$67.75M	$27.50M	$11.12M
YoY Change	509.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$139.0K	$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00
YoY Change
Total Long-Term Assets	$139.0K	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$67.75M	$27.50M	$11.12M
Total Long-Term Assets	$139.0K	$0.00	$0.00
Total Assets	$67.89M	$27.50M	$11.12M
YoY Change	510.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.800M	$700.0K	$1.000M
YoY Change	180.0%
Accrued Expenses	$0.00	$500.0K	$1.200M
YoY Change	-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$300.0K	$2.000M
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.800M	$3.223M	$4.869M
YoY Change	-42.49%	-21.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$2.900M
YoY Change	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$2.900M
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.800M	$3.223M	$4.869M
Total Long-Term Liabilities	$0.00	$0.00	$2.900M
Total Liabilities	$2.792M	$3.223M	$7.800M
YoY Change	-64.21%	-21.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.81M	-$17.12M	-$8.372M
YoY Change	291.87%	283.34%
Common Stock	$97.90M	$37.00M	$11.69M
YoY Change	737.18%	25242.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$65.09M	$24.28M	$3.322M
YoY Change
Total Liabilities & Shareholders Equity	$67.89M	$27.50M	$11.12M
YoY Change	510.59%

Cashflow Statement

Concept	2017 Q3	2016 Q4	2016 Q3
OPERATING ACTIVITIES
Net Income	-$6.940M	-$8.748M	-$1.870M
YoY Change	271.12%	860.26%	161.17%
Depreciation, Depletion And Amortization	$0.00
YoY Change
Cash From Operating Activities	-$4.770M	-$2.260M	-$570.0K
YoY Change	736.84%	326.42%	-45.19%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$15.85M	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$15.88M	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	70.00K	18.65M	11.68M
YoY Change	-99.4%	3418.87%	284.21%
NET CHANGE
Cash From Operating Activities	-4.770M	-2.260M	-570.0K
Cash From Investing Activities	-15.88M	0.000	0.000
Cash From Financing Activities	70.00K	18.65M	11.68M
Net Change In Cash	-20.58M	16.39M	11.11M
YoY Change	-285.24%	-7039451398144001000.0%
FREE CASH FLOW
Cash From Operating Activities	-$4.770M	-$2.260M	-$570.0K
Capital Expenditures	-$20.00K
Free Cash Flow	-$4.750M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	us-gaap	Assets Current AssetsCurrent	67746000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	27499000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67885000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27499000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4596000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1814000	USD
CY2017Q3	ck0001680048	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	0	USD
CY2016Q4	ck0001680048	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	413000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	2792000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	3223000	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2016Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	4396000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	36998000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17120000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	24276000	USD
CY2017Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	414000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	USD
CY2017Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	34088000	USD
CY2016Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	0	USD
CY2017Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	33209000	USD
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	27499000	USD
CY2017Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2188000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1718000	USD
CY2017Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	300000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7084000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3532000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	144000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-374000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3906000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	97897000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32807000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	65093000	USD
CY2016Q4	us-gaap	Assets Assets	27499000	USD
CY2017Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2723000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	683000	USD
CY2017Q3	us-gaap	Assets Assets	67885000	USD
	us-gaap	Operating Expenses OperatingExpenses	3532000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16056000	USD
CY2017Q3	us-gaap	Interest Income Other InterestIncomeOther	144000	USD
CY2016Q3	us-gaap	Interest Income Other InterestIncomeOther	0	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1870000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26186924	shares
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5388000	USD
CY2016Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2375000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1101000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8293000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	7084000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	1670000	USD
	us-gaap	Operating Expenses OperatingExpenses	16056000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1670000	USD
	us-gaap	Interest Income Other InterestIncomeOther	369000	USD
	us-gaap	Interest Income Other InterestIncomeOther	0	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-200000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	369000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15687000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10089269	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24936626	shares
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6940000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1234000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55970000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5674000	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	1682000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1230000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1923000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1025000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-56000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	375000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-413000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	278000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7781000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1866000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2375000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36485000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	320000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	3533000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49976000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12984000	USD
	us-gaap	Stock Issued1 StockIssued1	4396000	USD
	us-gaap	Stock Issued1 StockIssued1	190000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2375000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	1234000	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	274000	USD
	us-gaap	Interest Paid Net InterestPaidNet	413000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	414000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	0	USD
	ck0001680048	Stock Issuable For License Acquired StockIssuableForLicenseAcquired	1682000	USD
	ck0001680048	Stock Issuable For License Acquired StockIssuableForLicenseAcquired	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1230000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	34088000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	7039109	shares
	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	920191	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	ck0001680048	Warrants Issued WarrantsIssued	2134193	shares
CY2017Q1	ck0001680048	Warrants Issued WarrantsIssued	16000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	(1.1)
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5730000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	834000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
	ck0001680048	Class Of Warrant Or Right Percentage Of Warrant Issued ClassOfWarrantOrRightPercentageOfWarrantIssued	0.25	pure
CY2016Q4	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding	2243664	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3013770	shares
CY2017Q3	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding	5257434	shares
CY2016Q4	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instrument Other Than Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice	7.98
CY2017Q3	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instrument Other Than Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsOutstandingWeightedAverageExercisePrice	8.28
CY2017Q3	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instrument Other Than Options Granted Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsGrantedWeightedAverageExercisePrice	8.5
	ck0001680048	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Granted In Period Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageRemainingContractualTerms	P4Y4M2D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P5Y1M28D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y4M13D
CY2017Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	35000	USD
CY2016Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	0	USD
CY2017Q3	ck0001680048	Common Shares Issuable Liability Current CommonSharesIssuableLiabilityCurrent	0	USD
CY2016Q4	ck0001680048	Common Shares Issuable Liability Current CommonSharesIssuableLiabilityCurrent	1682000	USD
CY2017Q3	ck0001680048	Interest Income Expenses Related Party InterestIncomeExpensesRelatedParty	0	USD
CY2016Q3	ck0001680048	Interest Income Expenses Related Party InterestIncomeExpensesRelatedParty	-46000	USD
	ck0001680048	Interest Income Expenses Related Party InterestIncomeExpensesRelatedParty	0	USD
	ck0001680048	Interest Income Expenses Related Party InterestIncomeExpensesRelatedParty	-220000	USD
CY2017Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	156000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25232139	shares
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	0	shares
CY2016Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	767264	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25232139	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15165244	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15165244	shares
	us-gaap	Interest Expense Debt InterestExpenseDebt	156000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	USD
CY2016Q2	ck0001680048	Founders Agreement Term FoundersAgreementTerm	P15Y
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	90000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	35000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	22000	USD
	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	129000	USD
	ck0001680048	Proceeds From Notes Payable Gross ProceedsFromNotesPayableGross	0	USD
	ck0001680048	Proceeds From Notes Payable Gross ProceedsFromNotesPayableGross	3600000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50296000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11083000	USD
	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	117000	USD
	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	634000	USD
CY2016Q3	us-gaap	Professional Fees ProfessionalFees	17500	USD
	us-gaap	Professional Fees ProfessionalFees	30300	USD
CY2017Q3	us-gaap	Officers Compensation OfficersCompensation	12500	USD
	us-gaap	Officers Compensation OfficersCompensation	25052	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1963000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	5.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.773	pure
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5674000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1500000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1500000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Professional Fees ProfessionalFees	90000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	500000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	500000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The remaining 50% (“The Performance Options”) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company’s achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company’s achievement of a fully-diluted market capitalization of $1,000,000,000.
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5710000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11118000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27499000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33209000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11118000	USD
CY2017Q1	ck0001680048	Research And Development Expense Sponsored Research Payment ResearchAndDevelopmentExpenseSponsoredResearchPayment	2000000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	139000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2017Q3	ck0001680048	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	69000	USD
CY2016Q4	ck0001680048	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	445000	USD
	ck0001680048	Adjustment To Additional Paid In Capital Capital Contribution AdjustmentToAdditionalPaidInCapitalCapitalContribution	2062000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2062000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017Q3	ck0001680048	Property Plant And Equipment Design Costs Capitalized PropertyPlantAndEquipmentDesignCostsCapitalized	100000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1700000	USD
	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	2100000	USD
	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	100000	USD
CY2017Q3	ck0001680048	Number Of Shares To Be Issued Upon Legal Settlement NumberOfSharesToBeIssuedUponLegalSettlement	200000	shares
CY2017Q3	us-gaap	Professional Fees ProfessionalFees	60000	USD

Files In Submission

Name	View Source	Status
0001144204-17-058634-index-headers.html	Edgar Link	pending
0001144204-17-058634-index.html	Edgar Link	pending
0001144204-17-058634.txt	Edgar Link	pending
0001144204-17-058634-xbrl.zip	Edgar Link	pending
ck0001680048-20170930.xml	Edgar Link	completed
ck0001680048-20170930.xsd	Edgar Link	pending
ck0001680048-20170930_cal.xml	Edgar Link	unprocessable
ck0001680048-20170930_def.xml	Edgar Link	unprocessable
ck0001680048-20170930_lab.xml	Edgar Link	unprocessable
ck0001680048-20170930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv477598_10q.htm	Edgar Link	pending
tv477598_ex10-1.htm	Edgar Link	pending
tv477598_ex10-1img1.jpg	Edgar Link	pending
tv477598_ex10-1img2.jpg	Edgar Link	pending
tv477598_ex31-1.htm	Edgar Link	pending
tv477598_ex31-2.htm	Edgar Link	pending
tv477598_ex32-1.htm	Edgar Link	pending
tv477598_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBIO
MUSTANG BIO, INC. Stock $mbio

2017 Q3 Form 10-Q Financial Statement

#000114420417058634 Filed on November 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO MUSTANG BIO, INC. Stock $mbio

2017 Q3 Form 10-Q Financial Statement

#000114420417058634 Filed on November 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO
MUSTANG BIO, INC. Stock $mbio